title: Treatment strategy in schizophrenia combined with eating disorder.
abstract: Like any other patient, a schizophrenic patient can get a physical illness, too. As such patients tend to ignore reality and neglect themselves and are stigmatized by society, due to which their physical symptomatology is often ignored, physical illness can remain undetected. If the schizophrenic patient is observed and adequate care is provided by the family, family doctor and a psychiatrist, it is possible to recognize the physical illness and intervene promptly. We are presenting a case of a female patient who has been treated for schizophrenia for a number of years. The treatment was mostly ambulatory (i.e. the patient was hospitalized twice) and consisted of first-generation antipsychotics. During the past two years, for reasons unknown, the patient stopped taking regular meals and as a result lost significant body weight, became apathetic and withdrawn, started avoiding social contacts and neglected personal hygiene. She reportedly took the psychopharmaca regularly, but rarely attended psychiatric follow-up consultations. Due to substantial weight loss and hypotonia, correction of antipsychotic was made and internist treatment administered. The choice of olanzapine was not an accidental one. We decided to take advantage of its side effect for the treatment of an anorectic syndrome. Interdisciplinary cooperation proved to be a justified decision.
authors: Community Primary Health Centre, Primorsko-goranska county, Rijeka, Croatia. elizabeta.dadic.hero@ri.t-com.hr
authors: Elizabeta
authors: E
authors: Dadić-Hero
authors: Klementina
authors: K
authors: Ružić
authors: Tanja
authors: T
authors: Grahovac
authors: Toni
authors: T
authors: Valković
authors: Duška
authors: D
authors: Petranović
mesh_terms: D000328:Adult; D000856:Anorexia Nervosa / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D057565:Apathy / Q000187:drug effects; D001569:Benzodiazepines / Q000627:therapeutic use*; D015897:Comorbidity; D003299:Cooperative Behavior; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D057915:Drug Substitution / Q000523:psychology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D033183:Interdisciplinary Communication; D051346:Mobility Limitation; D000077152:Olanzapine; D017374:Paroxetine / Q000627:therapeutic use; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D012934:Social Isolation / Q000523:psychology; D014805:Vitamin B 12 / Q000627:therapeutic use; D015431:Weight Loss / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D017374:Paroxetine; D000077152:Olanzapine; D014805:Vitamin B 12